Edoxaban Monotherapy in Nonvalvular Atrial Fibrillation Patients with Coronary Artery Disease

Table 2

Primary and secondary endpoints, per study group.

	Edoxaban monotherapy; (n = 74)	Combination therapy; (n = 73)	Hazard ratio; (95% CI)	value
Primary endpoint
Major bleeding or clinically significant bleeding	2 (1.67) (major bleeding: 0)	5 (4.28) (major bleeding: 0)	0.39 (0.08–2.02)	0.26
Secondary endpoints
Cardiovascular event (s)
Myocardial infarction, stent thrombosis, and unstable angina requiring revascularization	0	0
Ischemic or systemic stroke and cardiovascular death	1	0
Myocardial infarction	0	0
Stent thrombosis
Unstable angina requiring revascularization	0	0
Ischemic stroke and systemic embolism	0	0
Minor bleeding	4 (3.35)	4 (3.43)	0.43; (0.13–1.41)	0.97
Death
Cardiovascular	1	0
Noncardiovascular	2 (1.66)	1 (0.86)	1.99; (0.18–21.9)	0.58

Values are the number of patients (% per patient-year). CI, confidence interval.